Search Medical Condition
Please enter condition
Please choose location from dropdown

Dyskinesias Clinical Trials

A listing of Dyskinesias medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (65) clinical trials

The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of PD patients who continue to have dyskinesia on amantadine.

Phase

Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one or more psychiatric disorders and a cumulative lifetime exposure to antipsychotic medication of three ...

Phase N/A

People with Dyskinesia due to their Parkinson’s disease medication are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.  

Phase N/A

Suffer from Parkinson’s-related LID? Learn more about a clinical trial for levodopa-induced dyskinesia. Right now, the gLIDe clinical research study is enrolling adults with Parkinson’s Disease who have levodopa-induced dyskinesia (involuntary movements). Researchers are testing an investigational drug to learn whether it may relieve this effect in these patients. People ...

Phase N/A

Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease

Traditionally amantadine is used at the beginning of Parkinson Disease (PD) treatment in the early stages of the disease, as a modest antiparkinsonian symptomatic treatment. This treatment is usually maintained for no more than the first few months of management, before resorting to drugs deemed more effective as dopamine agonists ...

Phase

Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease

Parkinson's disease (PD) is the most common neurodegenerative movement disorder of aging. Its cause is unknown. Current evidence supports a stress-diathesis model of pathogenesis whereby some yet-to-be identified environmental trigger conspires with a permissive genetic background to initiate the disease process. Based on neuropathological observations in other neurodegenerative diseases, such ...

Phase N/A

ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

The purpose of this study is to evaluate the safety and initial effectiveness of MRI-guided focused ultrasound thermal ablation of a designated area in the brain of patients suffering from movement disorder symptoms: FUS under MRI-guidance and MRI-based thermometry can be safely delivered to patients suffering from treatment-refractory movement disorders ...

Phase N/A

To Compare the Effectiveness of 3 Different Types of Lens and Lens Coating in Eliminating Symptoms for Children With Prolonged Visual Symptoms Due to a Concussion.

Recent studies have shown children who sustain a concussion are susceptible to having chronic symptoms (post-concussion syndrome). This chronicity can lead to delays in returning to learn and returning to play. Blurry vision, double vision, eye strain and eye tracking problems are some of the reported chronic symptoms that can ...

Phase N/A

High Resolution Micro OCT Imaging

Lung Disease is the predominate cause of morbidity and mortality in patients with cystic fibrosis (CF). A better understanding of the primary pathogenesis of CF is essential in order to reveal the features that may lead to the onset of progressive lung disease. Discerning the nature of the CF defect ...

Phase N/A

Predictive Factors of Unpredicted Movement in Motor Evoked Potential

Despite advances in neuroendovascular techniques, several complications can occur by brain urgery. Therefore, for neurosurgeons and anesthesiologists, it is a major concern to describe and monitor surgical lesion for maintaining structural and functional integrity as well as achieving maximal cytoreduction in lesion, and modifying the management of patients on the ...

Phase N/A